Target, across the briefings
IGF1R across 3 cancers
IGF1R is on the target list of 3 of the briefings. No drug aimed at it carries an FDA label naming any of them; a drug against it is approved somewhere in 3.
| Disease | Label status | Furthest stage (Open Targets) | Distinct drugs | Cell-therapy trials |
|---|---|---|---|---|
| Ewing sarcoma | approved elsewhere | approved | 20 | 0 via IGF-1R |
| Osteosarcoma | approved elsewhere | approved | 20 | 0 via IGF-1R |
| Rhabdomyosarcoma | approved elsewhere | approved | 20 | 0 via IGF-1R |
"Approved here" means a drug Open Targets records as aimed at IGF1R carries an FDA label that names that disease, per the briefing's openFDA stage. "Approved elsewhere" means the drug is approved for some other indication. Stage is the furthest Open Targets clinical stage among drugs aimed at the gene, in any indication; the database is reported as it is, and it lags some approvals. Cell-therapy trials are counted on the antigen the briefing maps the gene to, from ClinicalTrials.gov.